Sunday, September 25, 2016 11:38:40 AM
$ZSAN, .80 curing up from bottom w/Q1 Catalyst, watch for volume, chart:
ClinicalTrials.gov ID NCT02745392 for pivotal P2/3 (ZOTRIP) trial evaluating three doses vs. placebo w/ results expected during 1Q17 for the acute treatment of migraine headaches, being developed as novel skin patch formulation of approved migraine drug that is applied to upper arm during an acute migraine attack, plans to conduct long-term safety study if P2/3 efficacy data is positive with anticipated completion by 2Q18 to support a planned 505(b)(2) NDA filing by 3Q18
[/img]
ClinicalTrials.gov ID NCT02745392 for pivotal P2/3 (ZOTRIP) trial evaluating three doses vs. placebo w/ results expected during 1Q17 for the acute treatment of migraine headaches, being developed as novel skin patch formulation of approved migraine drug that is applied to upper arm during an acute migraine attack, plans to conduct long-term safety study if P2/3 efficacy data is positive with anticipated completion by 2Q18 to support a planned 505(b)(2) NDA filing by 3Q18
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
